Replies to post #132041 on Biotech Values

[genisi]

The first three Novartis QVA149 Phase III studies for approval in the EU and Japan in the treatment of COPD met their primary endpoints:

http://www.novartis.com/newsroom/media-releases/en/2012/1599186.shtml